Weaver Consulting Group
EW icon

Weaver Consulting Group’s Edwards Lifesciences EW Stock Holding History

Weaver Consulting Group’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.04M Sell
46,820
-195
-0.4% -$17.3K 0.79% 32
2026
Q2 		$4.25M Sell
47,015
-234
-0.5% -$19.6K 0.87% 31
2026
Q1 		$3.78M Sell
47,249
-318
-0.7% -$26.2K 0.9% 28
2025
Q4 		$4.06M Buy
47,567
+1,198
+3% +$98.3K 0.99% 26
2025
Q3 		$3.61M Sell
46,369
-10
-0% -$781 0.92% 30
2025
Q2 		$3.63M Sell
46,379
-206
-0.4% -$15.4K 1% 28
2025
Q1 		$3.38M Sell
46,585
-350
-0.7% -$25.1K 1.02% 24
2024
Q4 		$3.47M Sell
46,935
-558
-1% -$39.1K 1.07% 23
2024
Q3 		$3.13M Sell
47,493
-359
-0.8% -$26.1K 1% 26
2024
Q2 		$4.42M Buy
47,852
+8,400
+21% +$744K 1.54% 15
2024
Q1 		$3.77M Sell
39,452
-1,000
-2% -$84K 1.4% 17
2023
Q4 		$3.08M Sell
40,452
-2,185
-5% -$152K 1.25% 20
2023
Q3 		$2.95M Buy
42,637
+1,524
+4% +$122K 1.33% 18
2023
Q2 		$3.88M Sell
41,113
-2
-0% -$174 1.71% 13
2023
Q1 		$3.4M Sell
41,115
-1
-0% -$79 1.56% 14
2022
Q4 		$3.07M Buy
41,116
+1,566
+4% +$121K 1.57% 13
2022
Q3 		$3.27M Buy
39,550
+76
+0.2% +$7.31K 1.88% 12
2022
Q2 		$3.75M Buy
39,474
+549
+1% +$56.8K 2.1% 10
2022
Q1 		$4.58M Buy
38,925
+200
+0.5% +$22.4K 2.22% 10
2021
Q4 		$5.02M Buy
38,725
+3
+0% +$350 2.42% 10
2021
Q3 		$4.38M Buy
38,722
+118
+0.3% +$13.5K 2.38% 9
2021
Q2 		$4M Buy
38,604
+780
+2% +$73.5K 2.25% 9
2021
Q1 		$3.16M Buy
37,824
+1,494
+4% +$126K 1.94% 12
2020
Q4 		$3.31M Buy
36,330
+675
+2% +$56K 2.07% 11
2020
Q3 		$2.85M Buy
35,655
+1,575
+5% +$123K 1.64% 11
2020
Q2 		$2.36M Sell
34,080
-663
-2% -$47.1K 1.37% 16
2020
Q1 		$2.18M Buy
34,743
+639
+2% +$46.1K 1.43% 14
2019
Q4 		$2.5M Buy
34,104
+1,365
+4% +$107K 1.34% 17
2019
Q3 		$2.37M Hold
32,739
– – 1.25% 19
2019
Q2 		$2.02M Sell
32,739
-390
-1% -$23.6K 1.1% 19
2019
Q1 		$2.04M Buy
+33,129
New +$1.89M 0.58% 28

Other funds holding EW

Ninety One (UK)
Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Birch Hill Investment Advisors
Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return
Seilern Investment Management
Seilern Investment Management London, United Kingdom $771M AUM 2.59% 1-Year Est. Return
Ninety One North America
Ninety One North America New York $2.13B AUM 8.8% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
ABN AMRO Investment Solutions
ABN AMRO Investment Solutions Paris Cedex 008 $13.2B AUM 30.55% 1-Year Est. Return
Ninety One
Ninety One Cape Town, South Africa $2B AUM 34.6% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Weaver Consulting Group's EW Position: Q3 2026 in Review

Weaver Consulting Group reduced its Edwards Lifesciences (EW) stake by 0.41% in Q3 2026, selling an estimated $17.3K and leaving 46,820 shares worth $4.04M. The position accounts for 0.79% of the portfolio, ranked #32.

Weaver Consulting Group first reported a position in EW in Q1 2019 and has held it in 31 quarters since. The position peaked at $5.02M in Q4 2021. 258 funds tracked by Wall St. Rank hold EW as of Q3 2026.

  • Weaver Consulting Group held 46,820 shares of Edwards Lifesciences worth $4.04M as of Q3 2026.
  • Weaver Consulting Group sold 195 Edwards Lifesciences shares in Q3 2026, an estimated $17.3K.
  • Edwards Lifesciences made up 0.79% of Weaver Consulting Group's portfolio in Q3 2026, its #32 holding.
  • Weaver Consulting Group first reported a position in Edwards Lifesciences in Q1 2019 and has held it in 31 quarters since.
  • Weaver Consulting Group's Edwards Lifesciences position peaked at $5.02M in Q4 2021.
  • 258 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on Weaver Consulting Group's 13F filing for Q3 2026, filed 7 Oct 2026.